Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NovoCure Ltd Director's Dealing 2022

Sep 12, 2022

31949_dirs_2022-09-12_19f969fd-0828-42a2-8de0-f2c6587ef447.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-09-09

Reporting Person: Leonard Frank X (Chief Development Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-09-09 Ordinary Shares S 1863 $88 Disposed 84150 Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard.